First line treatment of NSCLC with cindilimab reached the main end point

Akari complement inhibitor has been successfully used in the treatment of PNH in phase III; levetiracetam injection solution has obtained the drug registration approval; cornerstone pharmaceutical has started the clinical trial of PD-L1 inhibitor combined with FGFR4 inhibitor; scientists are expected to develop a new drug therapy for Clostridium difficile infection We focus on the latest development of pharmaceutical research and development, and provide timely and accurate information reference for R & D personnel Recently, akari therapeutics released positive interim data of C5 complement inhibitor nomacopan in the treatment of paroxysmal nocturnal hemoglobinuria phase III capstone study On the 13th, Cinda biology and Lilly pharmaceutical jointly announced that the combination of PD-1 inhibitor Dabusu ® (cindilimab injection) and chemotherapy in the first-line treatment of non squamous non-small cell lung cancer reached the main research end point in phase 3 clinical A few days ago, Moderna announced that its research cytomegalovirus vaccine (mrna-1647) in phase I clinical research, after the third vaccination, obtained 7 months of safety and immunogenicity positive results in the medium term At the same time, Moderna announced that the phase 2 dose confirmation study had been administered to the first subject Apellis pharmaceuticals announced that it is developing a C3 complement inhibitor, pegcetacopolan, which is superior to the approved therapy in the three-stage study of adult patients with paroxysmal nocturnal hemoglobinuria, significantly improving the average hemoglobin level of patients and reaching the main end point of the study Jichuan Pharmaceutical Group Co., Ltd., a subsidiary of Jichuan Pharmaceutical Co., Ltd., received the approval document for drug registration (5ml: 500mg) of zuelacetam concentrated solution for injection approved and issued by the State Food and Drug Administration on March 13, according to the announcement issued by Jichuan pharmaceutical Edaravone sodium chloride injection of Jiangsu zhengdafenghai pharmaceutical, a subsidiary of China biopharmaceutical, has been approved as the first imitation in China The approval of registration according to the new classification will be deemed as passing the consistency evaluation On November 11, Fosun Pharmaceutical announced that the recombinant anti-CTLA-4 all human monoclonal antibody injection developed by Fuhong Hanlin, a holding subsidiary, and Hanlin pharmaceutical was accepted by the clinical trial registration review of the State Food and drug administration On November 11, Lu Kang medicine announced that it had received the approval document for drug registration of calcium acetate granules issued by the State Food and drug administration At present, the listing application of four generic drugs (acceptance No cyhs1700687) of sinakase hydrochloride tablets of Jiangsu Jiayi Pharmaceutical Co., Ltd is "under review and approval" FDA announced approval for keysruda, a blockbuster PD-1 inhibitor developed by MSD, to treat certain high-risk non muscle invasive bladder cancer patients The US FDA announced that it approved the launch of ayvakit developed by blueprint medicines for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors Cornerstone pharmaceutical and blueprint medicine jointly announced the launch of their PD-L1 inhibitor cs1001 and fisogatinib in the treatment of locally advanced and metastatic HCC patients in phase 1B / 2 clinical trials, to evaluate the anti-tumor activity of targeted therapy and cancer immunotherapy in locally advanced and metastatic HCC patients At present, both parties have completed the first patient administration of the trial AstraZeneca and Mina therapeutics jointly announced that they will develop new drugs for the treatment of metabolic diseases based on Mina's small activated RNA development platform Versastem oncology announced that it has reached a global exclusive license agreement with Chugai Pharmaceutical Co., Ltd of Japan, and versastem has obtained the global development and promotion rights of Raf / MEK inhibitor ch5126766 developed by Chugai Recently, in a research report published in the international journal Proceedings of the National Academy of Sciences, scientists from New York City University and other institutions have studied or are expected to help develop new drugs for the treatment of Clostridium difficile infection According to a report published in science by researchers from Hebrew University and shaare Zedek medical center, the use of multiple antibiotics in patients with bacterial infection may promote the spread of drug resistance.